Fiala

Peptide library › Immune & inflammation

Zilucoplan

Also known as Zilbrysq

FDA-approved drugImmune & inflammation

Daily self-injected peptide for generalised myasthenia gravis, an autoimmune condition that causes muscle weakness.

What people use it for

What Zilucoplan does in the body

A ring-shaped peptide that blocks complement C5, stopping the immune damage at the junction between nerves and muscles.

Strength of evidence

Strong: the Phase 3 RAISE trial improved daily function and muscle strength.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2023. Carries a boxed warning for serious meningococcal infections; meningococcal vaccines are required and it's only available through a safety programme.

How it's taken

Route: Injection under the skin, once daily

How long it lasts (half-life): About 7 to 8 days

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Zilucoplan privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Zilucoplan in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Immune & inflammation